Comparative Pharmacology
Head-to-head clinical analysis: MILNACIPRAN HYDROCHLORIDE versus SAVELLA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MILNACIPRAN HYDROCHLORIDE versus SAVELLA.
MILNACIPRAN HYDROCHLORIDE vs SAVELLA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Milnacipran is a serotonin-norepinephrine reuptake inhibitor (SNRI) with approximately 3-fold higher potency for norepinephrine reuptake inhibition compared to serotonin. It does not significantly affect dopamine or other neurotransmitter reuptake.
Selective serotonin and norepinephrine reuptake inhibitor (SNRI); also weakly inhibits dopamine reuptake. Binds to serotonin and norepinephrine transporters, increasing their extracellular concentrations.
50 mg orally twice daily with food, increased to 100 mg twice daily based on tolerability and efficacy.
100 mg orally twice daily; may initiate at 50 mg twice daily and increase to 100 mg twice daily after 1 week.
None Documented
None Documented
Terminal elimination half-life is approximately 6-8 hours in young adults; prolonged to 10-15 hours in elderly or patients with renal impairment (CrCl <30 mL/min).
Approximately 11 hours for milnacipran (SAVELLA). In the context of twice-daily dosing, steady state is reached within 2-3 days.
Primarily renal: ~60% excreted unchanged in urine; ~23% as glucuronide conjugates; ~3% as other metabolites; biliary/fecal excretion accounts for <5%.
Renal excretion of unchanged drug and metabolites accounts for approximately 51-58% of the dose. Fecal excretion accounts for about 19-22%. The remainder is eliminated via other routes (e.g., oxidative metabolism and subsequent conjugation).
Category C
Category C
SNRI Antidepressant
SNRI Antidepressant